FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis

PHILADELPHIA, Sept. 24, 2020 /PRNewswire/ — Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis. SPIRO-2101, an […]

Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer

PHILADELPHIA, May 13, 2020 /PRNewswire/ — Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis (CF), today appointed Roland Kolbeck, PhD, as Chief Scientific Officer. Dr. Kolbeck is an accomplished biotech executive, specializing in respiratory sciences and drug discovery. His career spans more than 20 years of […]

Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership

Accomplished Leaders in Gene Therapy Join Team PHILADELPHIA, PA, January 26, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for respiratory diseases including cystic fibrosis, today announced the leasing of its new, expanded headquarters and laboratories in the robust gene and cell therapy epicenter of Philadelphia’s University City in Wexford Science + […]

Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference

Philadelphia, PA, October 28, 2021 – Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021), November 2-5. SP-101, an investigational […]